Please login to the form below

Not currently logged in
Email:
Password:

Chiesi extends research deal with NiKem

Chiesi Farmaceutici is to extend its research collaboration with NiKem Research, focused on developing treatments within the respiratory therapeutic area

Chiesi Farmaceutici is to extend its research collaboration with NiKem Research, focused on developing treatments within the respiratory therapeutic area.

The two companies have been working together since 2001, with the new deal extending their efforts until 2014.

The collaboration will see NiKem continue its work providing services such as design, lead optimisation and biochemical pharmacology within different therapeutic areas on a fee-for-service basis.

Italy-based Chiesi specialises in products for respiratory pathologies, special care medicine and cardiovascular diseases, with the extended NiKem agreement focused on respiratory illnesses such as asthma and COPD.

Giuseppe Giardina, CEO of NiKem, said: "The scientific and business relationship with Chiesi is rock solid and the current extension follows 10 years of continuous success for both parties in collaborating to identify novel compounds eligible to candidate status for clinical development."

6th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics